Illumina (NASDAQ:ILMN) Insider Sells $110,700.00 in Stock

by · The Markets Daily

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) insider Scott Davies sold 615 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the sale, the insider directly owned 20,953 shares of the company’s stock, valued at $3,771,540. This trade represents a 2.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Up 1.5%

Shares of ILMN traded up $2.56 during mid-day trading on Thursday, reaching $177.65. 2,913,168 shares of the stock traded hands, compared to its average volume of 2,004,443. The stock has a fifty day simple moving average of $148.74 and a 200 day simple moving average of $137.38. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $182.84. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The firm has a market cap of $26.88 billion, a price-to-earnings ratio of 32.30, a P/E/G ratio of 3.28 and a beta of 1.50.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Illumina

Several hedge funds have recently modified their holdings of ILMN. Elyxium Wealth LLC acquired a new position in shares of Illumina in the 4th quarter worth approximately $25,000. Board of the Pension Protection Fund purchased a new stake in Illumina during the fourth quarter valued at about $26,000. Creative Capital Management Investments LLC boosted its stake in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new position in shares of Illumina during the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in Illumina during the 4th quarter valued at about $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ILMN. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research note on Thursday, May 14th. Citigroup boosted their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Evercore restated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $125.00 to $185.00 in a research report on Wednesday, June 10th. Finally, Royal Bank Of Canada started coverage on Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $143.56.

Get Our Latest Report on ILMN

About Illumina

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Further Reading